.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,715,710

« Back to Dashboard

Claims for Patent: 8,715,710

Title:Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron
Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.
Inventor(s): Ng; Steven Y. (San Francisco, CA), Shen; Hui Rong (Fremont, CA), Heller; Jorge (Ashland, OR)
Assignee: Heron Therapeutics, Inc. (Redwood City, CA)
Application Number:13/552,083
Patent Claims: 1. A semi-solid pharmaceutical composition comprising a polyorthoester, 10-50 weight percent polyethylene glycol monomethyl ether having a molecular weight in a range of 200 to 4,000, and about 1-5 weight percent granisetron, the polyorthoester comprising subunits selected from: ##STR00023## where x is an integer from 1-4, the total amount of p is an integer from 1-20, s is an integer from 1-4, the mole percentage of .alpha.-hydroxyacid containing subunits in the polyorthoester is from about 0.1 to about 25 mole percent, and the polyorthoester has a molecular weight in a range of 1000 to 10,000.

2. A semi-solid pharmaceutical composition comprising a polyorthoester, 10-50 weight percent polyethylene glycol monomethyl ether having a molecular weight in a range of 200 to 4,000, and 1-5 weight percent granisetron, where the polyorthoester comprises alternating residues of 3,9 -diethyl-3,9-2,4,8,10-tetraoxaspiro[5.5] undecane-3,9-diyl: ##STR00024## and a diol-ate residue of triethylene glycol or of triethylene glycol diglycolide prepared by reacting triethylene glycol with from 0.5 to 10 molar equivalents of glycolide at 100-200.degree. C. for about 12 hours to 48 hours, where the mole percentage of glycolide-containing subunits in the polyorthoester is from about 0.1 to about 25 mole percent, and the polyorthoester has a molecular weight of 1000 to 10,000.

3. The semi-solid pharmaceutical composition of claim 1 or claim 2, wherein the polyethylene glycol monomethyl ether has a molecular weight of about 550.

4. The semi-solid pharmaceutical composition of claim 1 or claim 2, comprising from 2-3 weight percent granisetron.

5. The semi-solid pharmaceutical composition of claim 1 or claim 2, wherein the granisetron is in the form of a free base.

6. The semi-solid pharmaceutical composition of claim 1 or claim 2, wherein the granisetron is in the form of an acid addition salt.

7. The semi-solid pharmaceutical composition of claim 1 or claim 2, comprising 78.4 weight percent polyorthoester, 19.6 weight percent polyethylene glycol monomethyl ether and 2 weight percent granisetron.

8. The semi-solid pharmaceutical composition of claim 1 or claim 2, wherein the polyorthoester has a molecular weight of about 6,500.

9. The semi-solid pharmaceutical composition of claim 1 or claim 2, wherein the composition is stable upon irradiation.

10. The semi-solid pharmaceutical composition of claim 1 or claim 2, wherein the composition is stable upon sterilization.

11. The semi-solid pharmaceutical composition of claim 1 or claim 2, wherein the granisetron is in the form of a solid having a particle size of less than 100 microns.

12. The semi-solid pharmaceutical composition of claim 1 or claim 2, wherein the composition is capable of being dispensed from a 16-25 gauge needle.

13. The semi-solid pharmaceutical composition of claim 1 or claim 2, effective to release the granisetron in a sustained and controlled manner after administration.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc